BioCentury | Apr 15, 2021
Regulation

April 14 Quick Takes: GSK stops two trials of ICOS agonist; plus Trodelvy, Amylyx, Junshi, Jazz, MitoChem

...Inc. (NYSE:MRK) on the therapy. Two for TrodelvyFDA expanded the label for Trodelvy sacituzumab govitecan-hziy from Gilead Sciences Inc....
...who have previously received a platinum-containing chemotherapy and either a PD-1 or a PD-L1 inhibitor. Gilead...
...– Programmed cell death 1 ligand 1 BC Staff Trodelvy, sacituzumab govitecan (hRS7-SN-38, IMMU-132) Jazz Pharmaceuticals plc Amylyx Pharmaceuticals Inc. Gilead Sciences Inc. Sage...
BioCentury | Apr 14, 2021
Finance

Tango is latest target in string of biotech SPAC mergers: Data Byte

...future redemptions, plus $186 million through a PIPE from life sciences specialist investors and partner Gilead Sciences Inc....
BioCentury | Apr 14, 2021
Management Tracks

Management shuffle at Novavax; plus Skyhawk, Kyverna, Gemini and more

...as an executive partner. Bhargava was VP and head of the oncology therapeutic area at Gilead Sciences Inc....
BioCentury | Apr 13, 2021
Product Development

FDA requests more data from Provention; plus Iterum, Seagen-Genmab, Pfizer and Gilead

...the U.S.FDA approves Trodelvy for TNBCFDA approved Trodelvy sacituzumab govitecan-hziy, an ADC targeting TROP2 from Gilead Sciences Inc....
...tisotumab vedotin abrocitinib (PF-04965842) Xeljanz XR, tofacitinib extended release Trodelvy, sacituzumab govitecan (hRS7-SN-38, IMMU-132) Iterum Therapeutics plc Seagen Inc. Genmab A/S Pfizer Inc. Gilead Sciences Inc. Tissue...
BioCentury | Apr 6, 2021
Management Tracks

Memories of John Martin, plus AACR’s hot targets and a Bio€quity Europe preview: a BioCentury podcast

...of the latest BioCentury This Week podcast. BioCentury’s editors discuss the legacy of the former Gilead...
...Li what he learned from the friends, colleagues and peers of John Martin, who led Gilead Sciences Inc....
...decades. Martin, they say, was a visionary leader, an A+ chemist and a risk-taker who transformed Gilead...
BioCentury | Apr 2, 2021
Product Development

Chinese biotechs look to next-generation CAR T technologies to solve market challenges

...medicines by revenue. Yescarta axicabtagene ciloleucel from Gilead Sciences Inc....
...Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKEX:2196) and Gilead’s...
BioCentury | Apr 1, 2021
Deals

Gilead again partners with AbCellera, forging multitarget deal that draws on biotech’s growing tool kit

...IPO, COVID authorization and second Gilead deal in one year By Paul Bonanos, Associate Editor Gilead’s...
...with Lilly.AbCellera Biologics Inc. (NASDAQ:ABCL) will create antibodies against up to eight targets chosen by Gilead Sciences Inc....
...limited to specific therapeutic areas; he said the biotech “has a line of sight” to Gilead’s...
BioCentury | Apr 1, 2021
Management Tracks

Remembering Gilead’s John Martin, whose therapies saved ‘millions’

...John Martin, the visionary leader who transformed Gilead...
...HIV and HCV by Gilead’s drugs. “What Gilead...
...of Gilead’s HIV and HBV franchises, beginning with Gilead’s...
BioCentury | Mar 28, 2021
Finance

Launched by Pharmacyclics vets, preclinical cancer start-up Biomea Fusion seeks short path to IPO

...Menlo Therapeutics Inc., now Vyne Therapeutics Inc. (NASDAQ:VYNE); EVP of Chemistry Thorsten Kirschberg, a longtime Gilead Sciences Inc....
BioCentury | Mar 27, 2021
Regulation

March 26 Quick Takes: ADCs from Astellas-Seagen, Gilead under EMA review; plus Pfizer-Lilly, BrainStorm and Ilya

...to treat locally advanced or metastatic urothelial cancer previously treated with a PD-1/PD-L1 inhibitor and platinum-based chemotherapy. Gilead...
...ASG-22CE, ASG-22ME, asg-22m6e) Trodelvy, sacituzumab govitecan (hRS7-SN-38, IMMU-132) tanezumab (PF-4383119, RN 624, RN-624, ri 624) Astellas Pharma Inc. Seagen Inc. Gilead Sciences Inc. Pfizer...
Items per page:
1 - 10 of 4070
BioCentury | Apr 15, 2021
Regulation

April 14 Quick Takes: GSK stops two trials of ICOS agonist; plus Trodelvy, Amylyx, Junshi, Jazz, MitoChem

...Inc. (NYSE:MRK) on the therapy. Two for TrodelvyFDA expanded the label for Trodelvy sacituzumab govitecan-hziy from Gilead Sciences Inc....
...who have previously received a platinum-containing chemotherapy and either a PD-1 or a PD-L1 inhibitor. Gilead...
...– Programmed cell death 1 ligand 1 BC Staff Trodelvy, sacituzumab govitecan (hRS7-SN-38, IMMU-132) Jazz Pharmaceuticals plc Amylyx Pharmaceuticals Inc. Gilead Sciences Inc. Sage...
BioCentury | Apr 14, 2021
Finance

Tango is latest target in string of biotech SPAC mergers: Data Byte

...future redemptions, plus $186 million through a PIPE from life sciences specialist investors and partner Gilead Sciences Inc....
BioCentury | Apr 14, 2021
Management Tracks

Management shuffle at Novavax; plus Skyhawk, Kyverna, Gemini and more

...as an executive partner. Bhargava was VP and head of the oncology therapeutic area at Gilead Sciences Inc....
BioCentury | Apr 13, 2021
Product Development

FDA requests more data from Provention; plus Iterum, Seagen-Genmab, Pfizer and Gilead

...the U.S.FDA approves Trodelvy for TNBCFDA approved Trodelvy sacituzumab govitecan-hziy, an ADC targeting TROP2 from Gilead Sciences Inc....
...tisotumab vedotin abrocitinib (PF-04965842) Xeljanz XR, tofacitinib extended release Trodelvy, sacituzumab govitecan (hRS7-SN-38, IMMU-132) Iterum Therapeutics plc Seagen Inc. Genmab A/S Pfizer Inc. Gilead Sciences Inc. Tissue...
BioCentury | Apr 6, 2021
Management Tracks

Memories of John Martin, plus AACR’s hot targets and a Bio€quity Europe preview: a BioCentury podcast

...of the latest BioCentury This Week podcast. BioCentury’s editors discuss the legacy of the former Gilead...
...Li what he learned from the friends, colleagues and peers of John Martin, who led Gilead Sciences Inc....
...decades. Martin, they say, was a visionary leader, an A+ chemist and a risk-taker who transformed Gilead...
BioCentury | Apr 2, 2021
Product Development

Chinese biotechs look to next-generation CAR T technologies to solve market challenges

...medicines by revenue. Yescarta axicabtagene ciloleucel from Gilead Sciences Inc....
...Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKEX:2196) and Gilead’s...
BioCentury | Apr 1, 2021
Deals

Gilead again partners with AbCellera, forging multitarget deal that draws on biotech’s growing tool kit

...IPO, COVID authorization and second Gilead deal in one year By Paul Bonanos, Associate Editor Gilead’s...
...with Lilly.AbCellera Biologics Inc. (NASDAQ:ABCL) will create antibodies against up to eight targets chosen by Gilead Sciences Inc....
...limited to specific therapeutic areas; he said the biotech “has a line of sight” to Gilead’s...
BioCentury | Apr 1, 2021
Management Tracks

Remembering Gilead’s John Martin, whose therapies saved ‘millions’

...John Martin, the visionary leader who transformed Gilead...
...HIV and HCV by Gilead’s drugs. “What Gilead...
...of Gilead’s HIV and HBV franchises, beginning with Gilead’s...
BioCentury | Mar 28, 2021
Finance

Launched by Pharmacyclics vets, preclinical cancer start-up Biomea Fusion seeks short path to IPO

...Menlo Therapeutics Inc., now Vyne Therapeutics Inc. (NASDAQ:VYNE); EVP of Chemistry Thorsten Kirschberg, a longtime Gilead Sciences Inc....
BioCentury | Mar 27, 2021
Regulation

March 26 Quick Takes: ADCs from Astellas-Seagen, Gilead under EMA review; plus Pfizer-Lilly, BrainStorm and Ilya

...to treat locally advanced or metastatic urothelial cancer previously treated with a PD-1/PD-L1 inhibitor and platinum-based chemotherapy. Gilead...
...ASG-22CE, ASG-22ME, asg-22m6e) Trodelvy, sacituzumab govitecan (hRS7-SN-38, IMMU-132) tanezumab (PF-4383119, RN 624, RN-624, ri 624) Astellas Pharma Inc. Seagen Inc. Gilead Sciences Inc. Pfizer...
Items per page:
1 - 10 of 4070